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Summary 
Background The impact of COVID-19 on physical and mental health and employment after hospitalisation with acute 
disease is not well understood. The aim of this study was to determine the effects of COVID-19-related hospitalisation 
on health and employment, to identify factors associated with recovery, and to describe recovery phenotypes.
Methods The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a multicentre, long-term follow-up study of 
adults (aged ≥18 years) discharged from hospital in the UK with a clinical diagnosis of COVID-19, involving an 
assessment between 2 and 7 months after discharge, including detailed recording of symptoms, and physiological 
and biochemical testing. Multivariable logistic regression was done for the primary outcome of patient-perceived 
recovery, with age, sex, ethnicity, body-mass index, comorbidities, and severity of acute illness as covariates. A post-
hoc cluster analysis of outcomes for breathlessness, fatigue, mental health, cognitive impairment, and physical 
performance was done using the clustering large applications k-medoids approach. The study is registered on the 
ISRCTN Registry (ISRCTN10980107).
Findings We report findings for 1077 patients discharged from hospital between March 5 and Nov 30, 2020, who 
underwent assessment at a median of 5·9 months (IQR 4·9–6·5) after discharge. Participants had a mean age of 
58 years (SD 13); 384 (36%) were female, 710 (69%) were of white ethnicity, 288 (27%) had received mechanical 
ventilation, and 540 (50%) had at least two comorbidities. At follow-up, only 239 (29%) of 830 participants felt fully 
recovered, 158 (20%) of 806 had a new disability (assessed by the Washington Group Short Set on Functioning), and 
124 (19%) of 641 experienced a health-related change in occupation. Factors associated with not recovering were 
female sex, middle age (40–59 years), two or more comorbidities, and more severe acute illness. The magnitude of the 
persistent health burden was substantial but only weakly associated with the severity of acute illness. Four clusters 
were identified with different severities of mental and physical health impairment (n=767): very severe 
(131 patients, 17%), severe (159, 21%), moderate along with cognitive impairment (127, 17%), and mild (350, 46%). Of 
the outcomes used in the cluster analysis, all were closely related except for cognitive impairment. Three (3%) of 
113 patients in the very severe cluster, nine (7%) of 129 in the severe cluster, 36 (36%) of 99 in the moderate cluster, 
and 114 (43%) of 267 in the mild cluster reported feeling fully recovered. Persistently elevated serum C-reactive 
protein was positively associated with cluster severity.
Interpretation We identified factors related to not recovering after hospital admission with COVID-19 at 6 months after 
discharge (eg, female sex, middle age, two or more comorbidities, and more acute severe illness), and four different 
recovery phenotypes. The severity of physical and mental health impairments were closely related, whereas cognitive 
health impairments were independent. In clinical care, a proactive approach is needed across the acute severity spectrum, 
with interdisciplinary working, wide access to COVID-19 holistic clinical services, and the potential to stratify care.
Funding UK Research and Innovation and National Institute for Health Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
As of September, 2021, the number of reported cases of 
COVID-19 exceeds 225 million worldwide, with more 
than 4·6 million deaths. Of the 7·4 million UK cases, 
536 000 have been admitted to hospital.1 Over the course 
of the pandemic, in-hospital mortality has reduced from 
more than 30% initially to less than 20% currently,2 
leaving more than 300 000 post-hospitalisation survivors 
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of COVID-19 in the UK. It is well established that in 
survivorship cohorts of hospitalised patients following 
critical illness, prolonged morbidity with reduced 
functional status and impaired mental health persists for 
many years.3
The largest post-hospitalisation cohort study of 
COVID-19 survivors published to date (from Wuhan, 
China) reported ongoing symptoms at 6 months with a 
positive association with severity of acute illness.4 
However, even in the milder group (those not requiring 
supplemental oxygen), more than 80% had persistent 
symptoms at 6 months.4
In the UK, the Post-hospitalisation COVID-19 study 
(PHOSP-COVID) was established as a national 
consortium to understand and improve long-term health 
outcomes after COVID-19. In this first analysis, we report 
the outcomes at first review for patients hospitalised with 
COVID-19 (who were discharged between March and 
November, 2020). The aim was to determine the impact 
on health and employment, to identify factors associated 
with recovery, and to describe recovery phenotypes.
Methods 
Study design and participants 
This prospective, longitudinal cohort study recruited 
patients aged 18 years or older who were discharged from 
one of 53 National Health Service (NHS) hospitals 
between March 5 and Nov 30, 2020 across England, 
Northern Ireland, Scotland, and Wales after admission to 
a medical assessment or ward for confirmed or clinician-
diagnosed COVID-19. We excluded patients who had a 
confirmed diagnosis of a pathogen unrelated to the 
objectives of this study, who attended an accident and 
emergency department but were not admitted, or who 
had another life-limiting illness with life expectancy of 
less than 6 months, such as disseminated malignancy. 
The PHOSP-COVID study includes collection of routine 
clinical data with linkage to retrospective and prospective 
health and social care records (Tier 1), enhanced clinical 
data collection and research-specific biosampling (Tier 2), 
and recall of participants by genotype and phenotype for 
more detailed studies (Tier 3). Participants from Tier 2 
who have undergone careful phenotyping are included in 
this study. This exploratory analysis is restricted to 
participants who consented to attend two follow-up 
research visits within 1 year after discharge (Tier 2) in 
addition to routine clinical care. The current version of 
the study protocol is provided in appendix 2.
Written informed consent was obtained from all study 
participants. The study was approved by the Leeds West 
Research Ethics Committee (20/YH/0225) and is 
registered on the ISRCTN Registry (ISRCTN10980107).
Procedures 
Participants were invited to attend a research visit 
between 2 and 7 months (plus or minus 2 weeks) after 
Research in context
Evidence before this study
We searched PubMed for studies of the long-term effects of 
COVID-19 on individuals after hospitalisation, published up 
to March 22, 2021. We used the search terms (“COVID-19” 
and “hospital” and [“long-term” OR “sequelae” OR 
“consequences”] and “cohort”). We excluded studies that had 
less than 3 months of follow-up after hospital discharge, 
those with fewer than 500 participants, and those that 
considered only single-organ or system effects. The impact of 
COVID-19 on physical and mental health and employment 
after hospitalisation is not well understood. A large, single-
centre study from Wuhan, China, highlighted the burden of 
disease persisting at 6 months, with 63% experiencing 
persistent fatigue and 23% experiencing symptoms of anxiety 
and depression. Much remains unknown about the 
characteristics of those experiencing a prolonged recovery.
Added value of this study
To our knowledge, we report the first and largest multicentre 
study, involving a diverse cohort in terms of ethnicity and 
spectrum of acute illness severity. Participants were 
prospectively recruited and attended an in-person research visit 
to assess their physical, mental, and cognitive status at a median 
of 6 months after hospital discharge, including comparisons 
with pre-COVID-19 status. Our findings confirm a large burden 
of symptoms persisting at 5 months after discharge, but also 
highlight a substantial proportion of survivors reporting a new 
disability and disruption to employment. Predictors of not 
recovering included female sex, comorbidities, middle age, 
and requiring invasive mechanical ventilation during admission. 
The mental and physical health impairments were only weakly 
associated with the severity of acute illness. We progress the 
understanding of the burden of disease after hospitalisation 
from COVID-19 by describing four clusters of recovery 
phenotype, in terms of mental health, physical performance, 
and cognition. There were significant differences in perceived 
recovery, impact on health-related quality of life, occupation 
change due to health, and disability across the four clusters, 
and higher C-reactive protein levels among patients 
experiencing the most severe ongoing impairments.
Implications of all the available evidence
Our findings suggest that there are underlying mechanisms 
causing severe mental and physical impairments, independent 
of the degree of acute lung injury and potentially related to 
persisting systemic inflammation. Our data, along with 
previous reports, suggest that a proactive approach and holistic 
clinical care are needed owing to the large burden of health 
impairments. The four clusters highlight the potential to 
stratify and personalise care, and emphasise the need for wide 
access to interventions to improve mental, physical, and 
cognitive health.
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hospital discharge. Where possible, this was scheduled 
alongside clinical follow-up, and data from clinically 
collected assessments within 4 weeks of a research visit 
were used. A core set of data variables for Tier 2 were 
obtained from the clinical records if part of clinical care 
or at the research visit (when not performed clinically; 
appendix 1 pp 10–13). The list of Tier 2 outcome measures 
is shown in appendix 1 (p 10), indicating which measures 
are included in this analysis. Baseline data 
Patient demographics and characteristics of their acute 
COVID-19 admission, including results of a PCR test for 
SARS-CoV-2, treatments, and organ support received, were 
obtained from hospital notes by the study team at each site. 
The Index of Multiple Deprivation, a geographical measure 
of social deprivation, was obtained for each participant 
using their postcode.5 Severity of acute illness was 
determined by the highest level of organ support received 
while admitted, categorised using the WHO Clinical 
Progression Scale as class 3–4 (no continuous supplemental 
oxygen needed), class 5 (continuous supple mental oxygen 
only), class 6 (continuous positive airway pressure venti-
lation, bi-level positive airway pressure, or high-flow nasal 
oxygen), or class 7–9 (invasive mechanical ventilation or 
extra corporeal membrane oxygenation).6 For the purpose 
of this analysis, those receiving renal replacement therapy 
acutely were assigned to class 7–9. Only participants with 
complete data for date of admission, organ support during 
admission, sex at birth, and attendance at a research visit 
2–7 months after discharge were included in this analysis.
Outcomes 
The primary outcome measures assessed health status 
and patient-perceived recovery. Patient-reported outcomes 
Figure 1: Flow diagram of participants
BNP=brain natriuretic peptide. eGFR=estimated glomerular filtration rate. EQ-5D-5L=EuroQol five-dimension five-level questionnaire. FACIT=Functional Assessment 
of Chronic Illness Therapy. HbA1c=glycated haemoglobin. NT-BNP=N-terminal brain natriuretic peptide.
Physiological outcomes
574 pulmonary function tests
634 incremental shuttle walk test
970 short physical performance battery
938 Rockwood Clinical Frailty Scale
908 body-mass index
Questionnaire outcomes
861 patient symptom questionnaire
1017 Dyspnoea-12 
1036 FACIT Fatigue Scale
801 Brief Pain Inventory 
699 EQ-5D-5L
800 Washington Group Short Set on Functioning
1031 Generalized Anxiety Disorder 7-item scale
1029 Patient Health Questionnaire-9
1030 Post Traumatic Stress Disorder Checklist








1170 participants attended a research visit 2–7 months after hospital discharge
93 excluded from analysis
15 research visit more than 240 days from discharge date
78 missing WHO Clinical Progression Scale or sex
1077 included in analysis
WHO class 3–4 WHO class 5 WHO class 6 WHO class 7–9 Total
Demographics
Participants 226 (21·0%) 378 (35·1%) 185 (17·2%) 288 (26·7%) 1077
Age at admission, years 54·8 (15·0) 60·7 (12·5) 59·1 (12·8) 55·7 (10·9) 57·9 (13·0)
Missing data 3 7 8 9 27
Sex at birth
Female 115 (50·9%) 134 (35·4%) 59 (31·9%) 76 (26·4%) 384 (35·7%)
Male 111 (49·1%) 244 (64·6%) 126 (68·1%) 212 (73·6%) 693 (64·3%)
Ethnicity
White 148 (67·3%) 251 (70·3%) 130 (73·0%) 181 (64·6%) 710 (68·6%)
South Asian 48 (21·8%) 49 (13·7%) 28 (15·7%) 41 (14·6%) 166 (16·0%)
Black 18 (8·2%) 27 (7·6%) 13 (7·3%) 31 (11·1%) 89 (8·6%)
Mixed 5 (2·3%) 12 (3·4%) 2 (1·1%) 4 (1·4%) 23 (2·2%)
Other 1 (0·5%) 18 (5·0%) 5 (2·8%) 23 (8·2%) 47 (4·5%)
Missing data 6 21 7 8 42
Occupation status
Working full time 110 (54·5%) 172 (52·6%) 90 (53·9%) 175 (68·9%) 547 (57·6%)
Working part time 23 (11·4%) 31 (9·5%) 19 (11·4%) 21 (8·3%) 94 (9·9%)
Other occupation 
status
69 (34·2%) 124 (37·9%) 58 (34·7%) 58 (22·8%) 309 (32·5%)
Missing data 24 51 18 34 127
Health-care worker 52 (24·6%) 58 (18·2%) 30 (18·9%) 57 (21·3%) 197 (20·6%)
Missing data 15 59 26 21 121
IMD
1 (most deprived) 44 (19·9%) 84 (22·6%) 30 (17·0%) 57 (20·0%) 215 (20·4%)
2 43 (19·5%) 84 (22·6%) 51 (29·0%) 64 (22·5%) 242 (23·0%)
3 45 (20·4%) 63 (17·0%) 34 (19·3%) 60 (21·1%) 202 (19·2%)
4 47 (21·3%) 71 (19·1%) 30 (17·0%) 48 (16·8%) 196 (18·6%)
5 (least deprived) 42 (19·0%) 69 (18·6%) 31 (17·6%) 56 (19·6%) 198 (18·8%)
Missing data 5 7 9 3 24
(Table 1 continues on next page)
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were collected using the following validated question-
naires: EuroQol five-dimension five-level (EQ-5D-5L) 
questionnaire, including the EuroQol Visual Analogue 
Scale (EQ-VAS),7 the Generalized Anxiety Disorder 7-item 
scale (GAD-7),8 the Patient Health Questionnaire-9 
(PHQ-9),9 the Post Traumatic Stress Disorder Checklist 
(PCL-5),10 Dyspnoea-12,11 the Functional Assessment of 
Chronic Illness Therapy (FACIT) Fatigue Scale,12 the Brief 
Pain Inventory (BPI),13 and the Washington Group Short 
Set on Functioning (WG-SS; appendix 1 pp 11–13).14 In 
addition, participants completed a study-specific clinical 
questionnaire that asked about their general recovery, 
symptoms, and changes to their working status since their 
COVID-19 admission (appendix p 11). Patient recovery 
was assessed by asking the question “Do you feel fully 
recovered?” and patients could respond “Yes”, “No”, or 
“Unsure”. The Montreal Cognitive Assessment (MoCA),15 
the Rockwood Clinical Frailty Scale,16 the incremental 
shuttle walk test (ISWT),17 the short physical performance 
battery (SPPB),18 and body-mass index (BMI) were 
measured (appendix 1 pp 11–13). In addition, pulmonary 
function tests and biochemical tests, including C-reactive 
protein, brain natriuretic peptide (BNP) or N-terminal-
BNP (or both), and haematological and renal profiles, 
were done.
Statistical analysis 
Continuous variables were presented as median (IQR) 
or mean (SD). Binary and categorical variables were 
presented as counts and percentages. Participants were 
stratified by the severity of their acute COVID-19 illness 
(based on four independent categories defined by 
WHO), by number of pre-existing comorbidities, or by 
cluster (see methods below). Missing data were reported 
within each variable and per category. A χ² test was used 
to identify differences in proportions across multiple 
categories. For normally distributed continuous data, 
analysis of variance (ANOVA F-test) was used to test 
differences across categories, with Kruskal-Wallis tests 
used for non-normally distributed data.
We reported univariable and multivariable logistic 
regression with and without imputed data where 
applicable. Missing values in variables were handled 
using multiple imputation by chained equations, under 
the missing-at-random assumption. Ten sets, each with 
ten iterations, were imputed using the following variables: 
age, sex, ethnicity, Index of Multiple Deprivation, BMI 
(measured at the 2–7 month follow-up visit, and used as a 
surrogate for BMI at admission), severity (WHO Clinical 
Progression Scale), comorbidity categories,19 admission 
duration, treatment with steroids, treatment with 
antibiotics, treatment with therapeutic anticoagulation, 
and the outcome variable (self-reported recovery from 
COVID-19). Further models were done, including 
discharge to review time and without imputation of the 
outcome variable. Model derivation and validation was 
done in imputed datasets, with Rubin’s rules20 used to 
combine results. Patient-perceived recovery from 
COVID-19 was modelled using hierarchical multi variable 
logistic regression, with admission hospital incorporated 
as a random effect. Criterion-based model building used 
the following principles: relevant explanatory variables 
were identified a priori for exploration, interactions were 
checked at the first-order level and incorporated if 
significant, and the final model selection was informed 
by the Akaike Information Criterion and C-statistic, 
with appropriate assumptions checked, including the 
distribution of residuals. Sensitivity analyses were done 
WHO class 3–4 WHO class 5 WHO class 6 WHO class 7–9 Total
(Continued from previous page)
Clinical characteristics










<30 103 (56·3%) 166 (51·4%) 62 (39·0%) 113 (46·5%) 444 (48·9%)
≥30 80 (43·7%) 157 (48·6%) 97 (61·0%) 130 (53·5%) 464 (51·1%)
Missing data 43 55 26 45 169
Smoking status
Never smoker 111 (59·4%) 166 (54·2%) 80 (53·3%) 148 (59·7%) 505 (56·7%)
Ex-smoker 69 (36·9%) 136 (44·4%) 68 (45·3%) 97 (39·1%) 370 (41·5%)
Current smoker 7 (3·7%) 4 (1·3%) 2 (1·3%) 3 (1·2%) 16 (1·8%)
Missing data 39 72 35 40 186
Comorbidities
Number 1 (0–3) 2 (0–3) 1 (0–3) 1 (0–3) 2 (0–3)
0 77 (34·1%) 97 (25·7%) 49 (26·5%) 92 (31·9%) 315 (29·2%)
1 45 (19·9%) 75 (19·8%) 44 (23·8%) 58 (20·1%) 222 (20·6%)
≥2 104 (46·0%) 206 (54·5%) 92 (49·7%) 138 (47·9%) 540 (50·1%)
Cardiovascular 74 (32·7%) 176 (46·6%) 82 (44·3%) 123 (42·7%) 455 (42·2%)
Respiratory 56 (24·8%) 105 (27·8%) 54 (29·2%) 69 (24·0%) 284 (26·4%)
Type 2 diabetes* 30 (13·3%) 80 (21·2%) 40 (21·6%) 63 (21·9%) 213 (19·8%)
Neuro-psychiatric 40 (17·7%) 60 (15·9%) 37 (20·0%) 44 (15·3%) 181 (16·8%)
Renal and endocrine 23 (10·2%) 48 (12·7%) 11 (5·9%) 31 (10·8%) 113 (10·5%)
Admission
Duration, days 2 (1–6) 6 (4–9) 10 (6–15) 33 (21–53) 9 (4–21)
Missing data 0 0 0 1 1
PCR-positive for 
COVID-19
176 (84·2%) 319 (90·6%) 156 (92·3%) 243 (90·3%) 894 (89·5%)
Missing data 17 26 16 19 78
Systemic steroids 22 (10·2%) 115 (31·5%) 57 (32·8%) 107 (45·9%) 301 (30·5%)
Missing data 11 13 11 55 90
Antibiotic therapy 103 (47·5%) 313 (85·1%) 165 (91·7%) 260 (96·7%) 841 (81·3%)
Missing data 9 10 5 19 43
Anticoagulation† 32 (15·1%) 89 (24·5%) 63 (35·4%) 137 (56·8%) 321 (32·3%)
Missing data 14 14 7 47 82
Data are n (%), median (IQR), or mean (SD). Percentages are calculated by category after exclusion of missing data for 
that variable. WHO classes are as follows: 3–4=no continuous supplemental oxygen needed; 5=continuous 
supplemental oxygen only; 6=continuous or bi-level positive airway pressure ventilation or high-flow nasal oxygen; 
and 7–9=invasive mechanical ventilation or other organ support. IMD=Index of Multiple Deprivation. BMI=body-mass 
index. *Eight participants with type 1 diabetes (of which six were in WHO class 7–9) are included within the renal and 
endocrine comorbidity category. †Therapeutic dose anticoagulation; does not include intermediate doses that were 
not recorded.
Table 1: Comparison of participant demographics, clinical characteristics, and admission characteristics 
stratified by acute illness severity
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using complete-case data. The final model was presented 
as a forest plot with odds ratios (ORs) and 95% CIs.
In a post-hoc analysis, unsupervised clustering of patient 
symptom questionnaire, physical performance, and 
cognitive assessment data (Dyspnoea-12, FACIT, GAD-7, 
PHQ-9, PCL-5, SPPB, and MoCA as continuous variables) 
was undertaken using the clustering large applications 
k-medoids approach.21 Scores were centred, normalised, 
and transformed so that higher burden of disease 
represented higher values. A Euclidean distance metric 
was used, and the optimal number of clusters was chosen 
using a silhouette plot. Cluster membership was 
determined for each individual and characteristics were 
presented as stratified tables. Pearson correlation was used 
for the comparison between BMI and C-reactive protein.
All tests were two-tailed and p values of less than 0·05 
were considered statistically significant. We did not 
adjust for multiple testing. We used R (version 3.6.3) 
with the finalfit, tidyverse, mice, cluster, and recipes 
packages for all statistical analysis.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results 
1170 patients who were discharged from hospital 
between March 5 and Nov 30, 2020, after treatment for 
COVID-19, were assessed between Aug 14, 2020, and 
March 5, 2021; 1077 of these patients were included in 
the analysis (figure 1). Overall, the majority of 
participants were male and of white ethnicity (table 1). 
315 (29·2%) of 1077 had no comorbidities, 222 (20·6%) 
had one comorbidity, and 540 (50·1%) had at least two 
comorbidities. The most common comorbidities were 
WHO class 3–4 (n=226) WHO class 5 (n=378) WHO class 6 (n=185) WHO class 7–9 (n=288) Total (n=1077) Available data, n (%)
Time to review from discharge, days 182·5 (159·0–200·0) 168·0 (136·2–192·0) 176·0 (139·0–191·0) 179·0 (156·8–198·0) 176·0 (147·0–196·0) 1077 (100·0%)
Recovered from COVID-19?*
Yes 51 (30·9%) 102 (36·3%) 41 (28·5%) 45 (18·8%) 239 (28·8%) 830 (77·1%)
No 75 (45·5%) 126 (44·8%) 65 (45·1%) 163 (67·9%) 429 (51·7%) 830 (77·1%)
Not sure 39 (23·6%) 53 (18·9%) 38 (26·4%) 32 (13·3%) 162 (19·5%) 830 (77·1%)
Missing data 61 97 41 48 247 ··
Symptoms
Symptom count 10·0 (4·0–19·0) 7·0 (3·0–13·0) 8·0 (4·0–16·0) 9·0 (5·0–16·0) 9·0 (4·0–16·0) 861 (79·9%)
GAD7 >8 57 (26·8%) 72 (19·9%) 44 (25·3%) 80 (28·4%) 253 (24·5%) 1031 (95·7%)
PHQ-9 ≥10† 64 (30·2%) 79 (21·9%) 49 (28·0%) 90 (32·0%) 282 (27·4%) 1029 (95·5%)
PCL-5 ≥38† 29 (13·6%) 31 (8·5%) 21 (12·0%) 45 (16·3%) 126 (12·2%) 1030 (95·6%)
Dyspnoea-12 7·2 (9·4) 5·5 (7·7) 6·5 (8·8) 6·5 (8·8) 6·3 (8·6) 1017 (94·4%)
FACIT fatigue* 18·5 (14·3) 14·6 (12·1) 16·4 (13·1) 18·5 (13·4) 16·8 (13·2) 1036 (96·2%)
Cognitive impairment
MoCA <23 25 (13·5%) 66 (21·0%) 19 (12·8%) 40 (16·7%) 150 (16·9%) 888 (82·5%)
Physical performance
SPPB ≤10 93 (46·7%) 153 (44·9%) 68 (40·5%) 134 (51·1%) 448 (46·2%) 970 (90·1%)
ISWT % predicted† 50·4 (37·8) 50·1 (38·7) 44·7 (32·4) 39·4 (31·4) 46·2 (35·8) 634 (58·9%)
Organ function
FEV1 <80% predicted† 26 (28·6%) 43 (26·1%) 23 (28·4%) 58 (39·5%) 150 (31·0%) 484 (44·9%)
FVC <80% predicted† 30 (33·0%) 43 (26·4%) 25 (30·9%) 62 (42·5%) 160 (33·3%) 481 (44·7%)
TLCO <80% predicted* 3 (15·8%) 19 (30·2%) 6 (19·4%) 30 (53·6%) 58 (34·3%) 169 (15·7%)
KCO <80% predicted 2 (10·5%) 7 (10·9%) 2 (6·2%) 5 (8·5%) 16 (9·2%) 174 (16·2%)
BNP ≥100 ng/L or NT-BNP 
≥400 ng/L
8 (5·8%) 15 (7·2%) 8 (8·0%) 15 (8·5%) 46 (7·4%) 621 (57·7%)
HbA1C ≥6·0% (DCCT/NGSP)‡ 37 (27·2%) 90 (42·3%) 39 (41·1%) 47 (28·1%) 213 (34·9%) 611 (56·7%)
Systemic inflammation
CRP >5 mg/L 36 (21·3%) 59 (20·6%) 26 (20·0%) 59 (27·1%) 180 (22·4%) 804 (74·7%)
Data are n (%), median (IQR), or mean (SD). Percentages are calculated by category after exclusion of missing data for that variable. p values show the effect of illness severity on outcome measure. Patient 
outcomes were assessed at a median of 5·9 months (IQR 4·9–6·5) after hospital discharge. WHO classes are as follows: 3–4=no continuous supplemental oxygen needed; 5=continuous supplemental oxygen 
only; 6=continuous or bi-level positive airway pressure ventilation or high-flow nasal oxygen; and 7–9=invasive mechanical ventilation or other organ support. GAD7=Generalized Anxiety Disorder 7-item scale. 
PHQ-9=Patient Health Questionnaire-9. PCL-5=Post Traumatic Stress Disorder Checklist. FACIT fatigue=Functional Assessment of Chronic Illness Therapy Fatigue Scale. SPPB=short physical performance battery. 
ISWT=incremental shuttle walk test. CFS=Clinical Frailty Scale. MoCA=Montreal Cognitive Assessment. FVC=forced vital capacity. TLCO=transfer capacity of the lung for carbon monoxide. KCO=carbon monoxide 
transfer coefficient. BNP=brain natriuretic peptide. NT-BNP=N-terminal BNP. HbA1C=glycated haemoglobin. DCCT/NGSP=Diabetes Control and Complications Trial/National Glycohemoglobin Standardization 
Program. eGFR=estimated glomerular filtration rate. CRP=C-reactive protein. *p<0·0001. †p<0·05. ‡p<0·01.
Table 2: Primary outcome measures including patient-reported outcome measures and physiological and biochemical tests, stratified by acute illness severity
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cardiovascular, respiratory, and type 2 diabetes (table 1; a 
complete list of recorded comorbidities is shown in 
appendix 1, pp 14–15). The cohort demographics and 
pre-existing comorbidities were similar across the 
severity of acute illness categories, except for a higher 
proportion of males (73·6%) among those receiving 
mechanical ventilation (WHO class 7–9; table 1). Before 
their hospital admission, 641 (67·5%) of 950 participants 
were working either full-time (n=547) or part-time (n=94; 
appendix 1 p 16). The median length of stay was 9 days 
(IQR 4–21) and 894 (89·5%) of 999 patients had a 
positive PCR test for COVID-19 at the time of admission 
(table 1).
The primary outcome measures were assessed at a 
median of 5·9 months (IQR 4·9–6·5) after discharge 
from hospital (table 2). More than 50% of the cohort 
were obese (appendix 1 pp 18–20). Only 239 (28·8%) of 
830 individuals with available data described themselves 
as fully recovered. Of those working before COVID-19, 
113 (17·8%) of 641 were no longer working, and 
124 (19·3%) of 641 experienced a health-related change 
in their occupational status. Employment change was 
most associated with WHO class 7–9; 54 (47·8%) of 
113 were no longer working and 68 (54·8%) of 
124 experienced a health-related change in occupational 
status (appendix 1 p 16). 158 (19·6%) of 806 patients 
reported a new disability assessed by the WG-SS.
Factors associated with worse recovery, defined by 
patient-perceived recovery, were female sex, the presence 
of two or more pre-existing co-morbidities, and WHO 
class 7–9 during the acute illness (figure 2). Age had a 
non-linear association, with age groups <30 years and 
>70 years perceiving better recovery than those aged 
50–59 years (figure 2). Recovery was associated with a 
BMI of less than 30 kg/m² in the univariable and 
multivariable analyses, but not in imputed models 
(appendix 1 pp 21–22). There was no association between 
receiving systemic steroids during admission and 
recovery, nor between discharge to review time and 
recovery (appendix 1 p 33). The findings between the 
imputed and non-imputed models were similar 
(appendix 1 pp 21–22).
632 (92·8%) of 855 participants had at least one 
persistent symptom, with a median number of 
9 symptoms (IQR 4–16; appendix 1 pp 23, 34). The ten 
most commonly reported persistent symptoms recorded 
at follow-up were aching of muscles (pain), fatigue, 
physical slowing down, impaired sleep quality, joint pain 
or swelling, limb weakness, breathlessness, pain, 
short-term memory loss, and slowing down in thinking 
(appendix pp 23–24). The number of persistent Figure 2: Forest plot of the patient and admission characteristics associated with patient-perceived recovery 
after hospitalisation for COVID-19
ORs were calculated using hierarchical multivariable logistic Regression, with admission hospital incorporated as a 
random effect, and multiple imputation. Patient-perceived recovery from COVID-19 was assessed at a median of 
5·9 months (IQR 4·9–6·5) after discharge from hospital. Patient recovery was assessed by asking the question “Do 
you feel fully recovered?” and patients could respond “Yes”, “No”, or “Unsure”. ORs are presented on a log scale; 
bars represent 95% CIs. BMI=body-mass index. OR=odds ratio.



















































































































Figure 3: Clusters of mental, cognitive, and physical health impairments
Figure shows four cluster phenotypes by Z scores, where a higher Z score 
indicates a higher deficit (A); clusters for cognitive impairment versus symptoms 
and physical function (B); and an illustration of the four cluster phenotypes with 
associated demographics, symptoms, and physical function (C). CRP=C-reactive 
protein. FACIT=Functional Assessment of Chronic Illness Therapy. 
GAD7=Generalized Anxiety Disorder 7-item scale. MoCA=Montreal Cognitive 
Assessment. PCL-5=Post Traumatic Stress Disorder Checklist. PHQ-9=Patient 
Health Questionnaire-9. PTSD=post-traumatic stress disorder. SPPB=short 
physical performance battery.
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symptoms was highest in those with pre-existing 
comorbidities (median number of symptoms: 10 [5–17]), 
but was also high in those without pre-existing 
co-morbidity (median 7 [2–13]; appendix 1 pp 23–25).
Patient-reported outcome measures and measures of 
physical performance, pulmonary physiology, and 
biochemistry are shown in table 2, stratified by WHO 
Clinical Progression Scale (further details are provided in 
appendix 1, pp 18–20). More than 25% of the cohort had 
clinically significant symptoms of anxiety and depression, 
and 126 (12·2%) participants had symptoms of 
post-traumatic stress disorder. Physical performance 
measured as percentage of predicted ISWT was 46·2%, 
and 448 (46·2%) scored 10 or less on the SPPB, a marker 
of functional impairment. The severity of acute illness 
and patient-reported outcomes of mental health, 
breathlessness, fatigue, or pain, or cognitive impairment 
were mostly unrelated (table 2; appendix p 13). In WHO 
class 7–9, the percentage of predicted ISWT distance was 
lower, and there was a higher proportion of individuals 
with a percentage of predicted transfer capacity of the 
lung for carbon monoxide of less than 80%, but otherwise 
there were no clear association between measures of 
organ function at 5 months and the spectrum of acute 
severity of illness.
Patients reported their EQ-VAS score for overall health 
as being worse by 9·8 units (SD 18·9) at follow-up than 
before hospital admission, with the greatest decrement in 
WHO class 7–9 (p=0·0008). The greatest decreases for the 
EQ-5D-5L utility index and all the domains of the EQ-5D 
were also seen in WHO class 7–9 (appendix 1 pp 26–27, 35). 
A comparison between patient-estimated EQ-VAS pre-
hospitalisation and age-adjusted popu lation norms is 
shown in appendix 1 (p 36). At least a fifth of the cohort 
reached the threshold for a new disability, with at least one 
domain coded as “a lot of difficulty” or “cannot do it at all” 
on the WG-SS (appendix 1 p 28). 429 (56·9%) of 
767 reported significantly worse symptoms of fatigue, 
369 (48·1%) of 767 reported worse breathlessness, 
318 (41·8%) of 761 reported worse sleep, and 291 (38·7%) 
of 751 reported worse pain (appendix 1 p 29).
In a post-hoc analysis, we investigated phenotypes of 
patient-perceived recovery using patient-reported out-
come measures for symptoms, mental health including 
post-traumatic stress disorder, MoCA for cognitive 
impairment, and SPPB for physical performance, and 
identified four clusters: very severe mental and physical 
impairment, severe mental and physical impairment, 
moderate mental and physical impairment with 
cognitive impairment, and mild  (appendix 1 pp 30, 37–38). 
Of the outcomes used in the cluster analysis, all were 
closely associated except for cognitive impairment 
(figure 3, appendix pp 37–38). A comparison of 
demographics between clusters is shown in table 3. 
Respiratory and neuropsychiatric comorbidities were 
more common in the very severe and severe clusters, 
and rheumatological comorbidities were more common 







Cluster 4: mild Total
Participants 131 (17·1%) 159 (20·7%) 127 (16·6%) 350 (45·6%) 767 (100·0%)
Age, years* 55·0 (10·3) 55·0 (11·2) 63·2 (13·2) 57·0 (13·2) 57·2 (12·6)
Missing data 7 3 4 2 16
Sex*
Female 60 (45·8%) 73 (45·9%) 46 (36·2%) 99 (28·3%) 278 (36·2%)
Male 71 (54·2%) 86 (54·1%) 81 (63·8) 251 (71·7%) 489 (68·8%)
Ethnicity
White 94 (74·6%) 118 (78·1%) 77 (61·1%) 242 (71·2%) 531 (71·5%)
South Asian 12 (9·5%) 20 (13·2%) 25 (19·8%) 60 (17·6%) 117 (15·7%)
Black 11 (8·7%) 6 (4·0%) 15 (11·9%) 17 (5·0%) 49 (6·6%)
Mixed 2 (1·6%) 2 (1·3%) 3 (2·4%) 6 (1·8%) 13 (1·7%)
Other 7 (5·6%) 5 (3·3%) 5 (4·0%) 8 (2·4%) 25 (3·4%)
Missing data 5 8 1 10 24
IMD*
1 (most deprived) 37 (29·4%) 24 (15·2%) 31 (25·0%) 53 (15·2%) 145 (19·2%)
2 32 (25·4%) 36 (22·8%) 39 (31·5%) 67 (19·3%) 174 (23·0%)
3 19 (15·1%) 29 (18·4%) 19 (15·3%) 80 (23·0%) 147 (19·4%)
4 20 (15·9%) 32 (20·3%) 22 (17·7%) 72 (20·7%) 146 (19·3%)
5 (least deprived) 18 (14·3%) 37 (23·4%) 13 (10·5%) 76 (21·8%) 144 (19·0%)
Missing data 5 1 3 2 11
BMI ≥30 kg/m²* 79 (68·1%) 86 (60·6%) 42 (38·2%) 136 (47·2%) 343 (52·3%)
Missing data 15 17 17 62 111
Smoking status
Never smoker† 61 (53·0%) 70 (51·5%) 65 (60·2%) 181 (62·2%) 377 (58·0%)
Ex-smoker 50 (43·5%) 61 (44·9%) 43 (39·8%) 109 (37·5%) 263 (40·5%)
Current smoker 4 (3·5%) 5 (3·7%) 0 (0·0%) 1 (0·3%) 10 (1·5%)
Missing data 16 23 19 59 117
Comorbidities
Number* 2 (1–4) 2 (1–3) 1 (0–3) 1 (0–2) 1 (0–3)
Cardiovascular 65 (49·6%) 68 (42·8%) 51 (40·2%) 128 (36·6%) 312 (40·7%)
Neuro-psychiatric* 53 (40·5%) 37 (23·3%) 12 (9·4%) 23 (6·6%) 125 (16·3%)
Respiratory* 56 (42·7%) 47 (29·6%) 23 (18·1%) 80 (22·9%) 206 (26·9%)
Rheumatology‡ 25 (19·1%) 16 (10·1%) 15 (11·8%) 27 (7·7%) 83 (10·8%)
Type 2 diabetes 26 (19·8%) 32 (20·1%) 24 (18·9%) 57 (16·3%) 139 (18·1%)










Missing data 0 0 0 1 1
WHO Clinical Progression Scale
Class 3–4 27 (20·6%) 38 (23·9%) 22 (17·3%) 67 (19·1%) 154 (20·1%)
Class 5 33 (25·2%) 53 (33·3%) 56 (44·1%) 132 (37·7%) 274 (35·7%)
Class 6 21 (16·0%) 24 (15·1%) 20 (15·7%) 61 (17·4%) 126 (16·4%)
Class 7–9 50 (38·2%) 44 (27·7%) 29 (22·8%) 90 (25·7%) 213 (27·8%)
PCR-positive for 
COVID-19
108 (89·3%) 127 (85·8%) 107 (89·2%) 292 (90·1%) 634 (88·9%)
Missing data 10 11 7 26 54
Data are n (%), median (IQR), or mean (SD). There was no relationship between other categories of comorbidities and 
cluster classification. p values represent the differences in characteristics between clusters. WHO classes are as follows: 
3–4=no continuous supplemental oxygen needed; 5=continuous supplemental oxygen only; 6=continuous or bi-level 
positive airway pressure ventilation or high-flow nasal oxygen; and 7–9=invasive mechanical ventilation or other 
organ support. IMD=Index of Multiple Deprivation. *p<0·0001. †p<0·05. ‡p<0·01.
Table 3: Baseline assessments including patient and admission characteristics of the four recovery 
clusters
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in the very severe cluster than in the other clusters. The 
Indices of Multiple Deprivation were worse in patients 
in the very severe and moderate clusters than in the 
severe and mild clusters. There was no association 
between cluster and WHO Clinical Progression Scale 
during the acute admission.
The patient-reported outcomes and physical perfor-
mance were different between the clusters (table 4). 
Impairments in lung physiology and biochemical tests 
used in the assessment of heart failure, renal failure, 
diabetes, and pre-diabetes, were observed in all the 
clusters, but none were discriminatory across clusters. In 
the whole cohort, 180 (22·4%) of 804 had persistent 
systemic inflammation, measured by C-reactive protein 
of more than 5 mg/L, which was weakly correlated with 
BMI (r=0·247; p<0·0001). Elevated C-reactive protein 
was more prevalent in the very severe and severe clusters, 
compared with the moderate and mild clusters.
The patient-perceived recovery was lowest in the very 
severe (three [2·7%] of 113 patients) and severe 
(nine [7·0%] of 129) clusters compared with the moderate 
(36 [36·4%] of 99) and mild (114 [42·7%] of 267) clusters 
(p<0·0001; appendix 1 pp 31–32). The EQ-VAS and utility 
index was lowest in the very severe cluster before 
COVID-19, with the greatest decreases between before 
COVID-19 and follow-up in the very severe and severe 
clusters (p<0·0001). There were higher rates of new 
disability (assessed by WG-SS) in the very severe 
cluster (57 [51·8%] of 110) compared with the severe 
cluster (25 [20·0%] of 125), the moderate cluster 
(11 [11·5%] of 96), and the mild cluster (12 [4·6%] of 262; 
p<0·0001). The very severe cluster had a greater proportion 
Cluster 1: very severe 
(n=131)
Cluster 2: severe 
(n=159)
Cluster 3: moderate and 
cognitive (n=127)
Cluster 4: mild (n=350) Total (n=767) Available data, n (%)
Time to review from 
discharge, days
174·0 (136·0–198·5) 175·0 (148·0–192·0) 176·0 (152·0–192·0) 176·0 (148·2–194·0) 175·0 (147·5–194·0) 767 (100·0%)
Persistent symptoms* 114 (100·0%) 131 (98·5%) 97 (91·5%) 230 (83·6%) 572 (91·1%) 628 (81·9%)
Symptom count* 20 (16–25) 13 (8–17) 7 (3–12) 5 (2–8) 8 (4–16) 628 (81·9%)
GAD-7 >8* 118 (90·1%) 44 (27·7%) 16 (12·6%) 4 (1·1%) 182 (23·7%) 767 (100·0%)
PHQ-9 ≥10* 128 (97·7%) 60 (37·7%) 9 (7·1%) 1 (0·3%) 198 (25·8%) 767 (100·0%)
PCL-5 ≥38* 79 (60·3%) 9 (5·7%) 2 (1·6%) 0 90 (11·7%) 767 (100·0%)
Dyspnoea-12* 18·2 (9·9) 6·7 (6·4) 4·2 (5·3) 1·6 (2·5) 5·9 (8·2%) 767 (100·0%)
FACIT fatigue* 34·9 (8·9) 23·8 (8·6) 11·2 (8·4) 7·0 (5·2) 15·9 (12·9) 767 (100·0%)
BPI severity* 21·5 (8·4) 13·9 (8·6) 11·7 (10·1) 7·3 (7·6) 12·1 (9·9) 587 (76·5%)
BPI interference* 39·9 (17·1) 21·2 (14·9) 14·1 (15·8) 6·7 (9·7) 17·5 (18·3) 574 (74·8%)
SPPB (mobility disability)* 94 (71·8) 72 (45·3) 67 (52·8) 101 (28·9) 334 (43·5) 767 (100·0%)
ISWT distance, m* 278 (190) 432 (258) 415 (226) 536 (262) 452 (261) 463 (60·4%)
CFS ≥5* 26 (22·8%) 2 (1·3%) 4 (3·5%) 4 (1·2%) 36 (5·1%) 702 (91·5%)
MoCA <23* 40 (30·5%) 2 (1·3%) 82 (64·6%) 0 124 (16·2%) 767 (100·0%)
Adjusted MoCA <23* 36 (27·5%) 1 (0·6%) 70 (55·1%) 0 107 (14·0%) 767 (100·0%)
FEV1 % predicted† 79·8 (20·9) 91·2 (35·5) 89·5 (20·8) 91·6 (17·5) 89·3 (24·2) 359 (46·8%)
FEV1 <80% predicted‡ 27 (49·1%) 23 (27·7%) 18 (26·1%) 34 (22·4%) 102 (28·4%) 359 (46·8%)
FVC <80% predicted‡ 30 (55·6%) 25 (30·1%) 20 (29·0%) 40 (26·3%) 115 (32·1%) 358 (46·7%)
FEV1/FVC <0·7 4 (6·1%) 11 (11·3%) 8 (10·8%) 14 (7·6%) 37 (8·8%) 421 (54·9%)
TLCO <80% predicted 8 (40·0%) 12 (36·4%) 7 (30·4%) 18 (27·7%) 45 (31·9%) 141 (18·4%)
KCO <80% predicted† 2 (9·5%) 7 (21·2%) 3 (12·5%) 2 (3·0%) 14 (9·7%) 144 (18·8%)
BNP/NT-BNP % greater than 
threshold§
5 (7·2%) 4 (4·0%) 5 (6·7%) 13 (6·7%) 27 (6·2%) 439 (57·2%)
HbA1C ≥6·0% (DCCT/NGSP) 27 (41·5%) 26 (27·4%) 29 (38·2%) 65 (33·0%) 147 (33·9%) 433 (56·5%)
eGFR <60 mL/min per 
1·73 m²
16 (15·5%) 11 (8·0%) 14 (13·7%) 35 (12·9%) 76 (12·4%) 615 (80·2%)
D-dimer ≥500 ng/mL 8 (9·5%) 14 (11·4%) 11 (11·6%) 30 (12·3%) 63 (11·5%) 546 (71·2%)
D-dimer, mg/L 276·0 (348·9) 240·1 (200·9) 274·1 (269·2) 290·2 (346·5) 273·9 (306·6) 546 (71·2)
CRP >5 mg/L‡ 29 (29·3%) 36 (27·9%) 17 (17·2%) 36 (14·3%) 118 (20·4%) 578 (75·4%)
Data are n (%), median (IQR), or mean (SD). Patient outcomes were assessed at a median of 5·9 months (IQR 4·9–6·5) after hospital discharge. p values represent differences between clusters. GAD7=Generalized 
Anxiety Disorder 7-item scale. PHQ-9=Patient Health Questionnaire-9. PCL-5=Post Traumatic Stress Disorder Checklist. FACIT fatigue=Functional Assessment of Chronic Illness Therapy Fatigue Scale. BPI=Brief 
Pain Inventory. SPPB=short physical performance battery. ISWT=incremental shuttle walk test. CFS=Clinical Frailty Scale. MoCA=Montreal Cognitive Assessment. Adjusted MoCA=MoCA adjusted for education. 
FVC=forced vital capacity. TLCO=transfer capacity of the lung for carbon monoxide. KCO=carbon monoxide transfer coefficient. BNP=brain natriuretic peptide. NT-BNP=N-terminal BNP. HbA1C=glycated 
haemoglobin. DCCT/NGSP=Diabetes Control and Complications Trial/National Glycohemoglobin Standardization Program. eGFR=estimated glomerular filtration rate. CRP=C-reactive protein. *p<0·0001. 
†p<0·05. ‡p<0·01. §Threshold BNP ≥100 ng/L or NT-BNP ≥400 ng/L.
Table 4: Primary outcome measures stratified by four recovery clusters 
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of people no longer working after hospitalisation with 
COVID-19 (50·0% versus 10·0% to 16·1% across the other 
clusters; p<0·0001), and the greater proportion of people 
who experienced a change in occupation due to health 
reasons after COVID-19 (60·0% versus 8·7% to 19·4% 
across the other clusters; p<0·0001; appendix 1 p 17).
Discussion 
This is the largest study, across multiple UK centres, 
to comprehensively report on prospectively assessed 
outcomes to describe the holistic impact of COVID-19 on 
the medium-term health of survivors. The majority of 
patients had not fully recovered, had persistent symptoms, 
and 20% had a new disability. In the two-thirds who were 
working before admission to hospital, 19% had changed 
working status, predominately due to ill health. Not fully 
recovering was associated with female sex, middle age 
(40–59 years), two or more comorbidities, and having 
received mechanical ventilation. Treatment with systemic 
corticosteroids was not associated with recovery. The 
magnitude of the ongoing mental and physical health 
burden was substantial but, perhaps surprisingly, several 
aspects of the ongoing health burden were unrelated to 
acute severity. Measures of pulmonary transfer factor, 
walking performance, and changes in health-related 
quality of life appeared worse in those who had received 
mechanical ventilation, but the impact on health status by 
symptoms (breathlessness, fatigue, pain, anxiety, and 
depression) and other measures of organ function were 
unrelated to acute illness severity. This finding led us to 
define further possible recovery phenotypes using cluster 
analysis, including validated tools for breathlessness, 
fatigue, mental health, cognitive impairment, and physical 
function. We identified four recovery clusters that tracked 
with severity of both mental and physical health 
impairment, except for cognitive impairment, which was 
largely independent. Whether these clusters have different 
underlying mechanisms and warrant different treatments 
and clinical pathways needs to be determined.
Our finding of 20–30% recovery at 6 months after 
hospitalisation for COVID-19 is consistent with previous 
reports.4,22 By contrast, in adults who were not 
hospitalised, recovery after COVID-19 is approximately 
70–90% in most studies at 3 months,23 suggesting that 
severity of the acute illness warranting hospitalisation is 
associated with a lower likelihood of recovery. The 
persistent symptom burden and proportion of patients 
not recovering at 6 months after hospitalisation from 
COVID-19 appears greater than was previously reported 
for older adults (mean age 62 years) hospitalised with 
community acquired pneumonia, who had a median 
recovery time of 3 weeks.24
We report an inconsistent relationship between the 
severity of the different health impairments and the 
severity of the acute illness, implying different underlying 
mechanisms. The degree of acute lung injury largely 
determines the level of respiratory support during the 
acute illness; it is therefore unsurprising that measures 
of pulmonary and physical function at 6 months are 
associated with the severity of acute illness. However, the 
same relationship is not observed for markers of cardiac 
or renal impairment, nor for the impact of persistent 
symptoms. We therefore suggest that although there is 
evidence of a post-intensive care unit syndrome 
consistent with other illnesses, other mechanisms are 
causing the ongoing symptoms across the acute severity 
spectrum, supported by the magnitude of persistent 
symptoms seen in those who were never hospitalised.25 
Based on our data, holistic post-hospital care pathways 
should be proactive, available to all hospitalised patients 
and not solely those who received ventilatory support, 
and should include symptom assessment.
Some of our reported associations with reduced 
patient-perceived recovery contrast with those associated 
with worse outcome during the acute illness. Consistent 
with a previous report for community-managed 
COVID-19,23 we found female sex was associated with not 
recovering, in contrast to male sex being a risk factor for 
more severe acute illness. Autoimmunity is more 
common in women older than 40 years, and both 
anti-cytokine and tissue-specific autoantibodies have 
been implicated in post-COVID syndromes;26–28 this is 
one possible explanation for the association that needs 
further investigation. Despite greater morbidity and 
mortality greater acute COVID-19 infection and increased 
risk post-discharge of cardiometabolic and respiratory 
events in ethnic minorities,29–31 there was no association 
with absence of full recovery. Age had a non-linear 
relationship with recovery, with those who were younger 
or older having a higher likelihood of recovery, whereas 
poor recovery was associated with middle age 
(40–59 years). Having two or more comorbidities was 
associated with both increased risk of severe acute illness 
and subsequent poor recovery post hospitalisation, and 
similarly, obesity appears to be a risk factor for both. 
Systemic corticosteroid therapy for the acute illness 
reduces mortality in those with more severe acute 
disease,32 but was not associated with post-discharge 
medium-term recovery.
The four recovery clusters we identified largely 
corresponded to severity of mental and physical health 
impairment, but cognitive impairment was largely 
independent. The independence of cognitive impairment 
has also been noted in the recovery trajectory for 
survivors of adult respiratory distress syndrome.33,34 Of 
note, the clusters were not closely related to acute illness 
severity in our study, further supporting the view that 
severity of persistent physical and mental ill health and 
cognitive impairment are due to mechanisms other than 
those directly related to severity of the acute lung injury 
(assessed in our cohort by the highest level of respiratory 
support using the WHO Clinical Progression Scale). 
Pre-COVID-19 poor health status and comorbidities 
including obesity were particularly a feature of the very 
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severe cluster and, to a lesser extent, the severe cluster, 
compared with the moderate and mild clusters. However, 
changes in EQ-VAS and utility index showed that the 
greatest impact on health status was in the very severe 
and severe clusters, even accounting for poorer health 
status before COVID-19. Objective tests of organ function 
were not discriminatory across the clusters except for 
percentage of predicted FEV1 and C-reactive protein 
levels. The percentage of predicted FEV1 was lower in the 
very severe cluster than in other clusters without evidence 
of airflow obstruction, suggesting that airflow restriction 
was possibly due to lung fibrosis or in part due to extra-
thoracic restriction secondary to obesity.
C-reactive protein was greater than 5 mg/L at 5 months 
in more than 22% of the cohort and was particularly 
elevated in the very severe and severe clusters compared 
with the mild cluster, possibly due to persistent systemic 
inflammation. We found only a weak correlation between 
BMI and C-reactive protein level, suggesting that 
although the elevated C-reactive protein in the very 
severe, severe, and moderate clusters might be partly due 
to increased BMI, this is unlikely to fully explain 
the increased systemic inflammation. Therefore, the 
magnitude of the physical and mental health impact, 
the heterogeneity of the cognitive impairment between 
and within these clusters, and the impact of persistent 
inflammation and its effect on the immunological 
response require more understanding of possible 
underlying mechanisms. In terms of clinical care, these 
four cluster phenotypes point to the potential of 
stratifying follow-up care and interventions according to 
the severity and causes of the impairments. For example, 
those in the mild cluster might need less intense follow-
up than those in the very severe cluster, and those with 
persistent inflammation or obesity might benefit from 
anti-inflammatory therapy or strategies to promote 
weight loss.35
Beyond the impact on health, working status changed 
for one in five patients, and a similar proportion 
experienced a health-related change in occupation. This 
impact on occupation was most marked in the group that 
had required mechanical ventilation, similar to findings 
from intensive therapy unit survivorship studies.36 In 
the recovery clusters, impact on occupation was most 
striking in the very severe cluster, from more than 
60% working before COVID-19 to around 50% having 
changed occupation after hospitalisation, almost entirely 
due to poor health.36 This societal impact is clearly 
substantial in those hospitalised but is also highly 
relevant for non-hospitalised cases of COVID-19.
The strengths of our large, multicentre study include 
the most comprehensive assessment of in-clinic and 
patient-reported outcomes to date, highlighting the 
inconsistent relationship between the severity of ongoing 
health impairments and the severity of the acute illness 
between different health domains, and enabling symptom 
cluster phenotyping. However, this study has a number of 
limitations. The patients represent a small sample of the 
total number of patients discharged from hospital after 
having COVID-19 in the UK. The study population is 
younger than the overall population in the UK that 
survived hospitalisation for COVID-19,37 and only 
included those able to attend clinic visits and undertake 
the study procedures. This acquisition bias might under-
represent the most severely affected patients, but 
conversely, those patients with ongoing symptoms might 
have been more willing to participate. Missing data were 
variable across the outcomes, with potential selection 
bias. The variation in time from discharge to assessment 
was broad and, although it did not affect patient-perceived 
recovery, the stability of the cluster phenotypes over time 
needs to be understood. The results need validating in a 
separate cohort, alongside understanding the association 
between cluster membership and future health outcomes. 
The patient-reported outcomes and physical and 
biological tests assessed cross-sectionally do not allow for 
a clear differentiation between the contribution from 
premorbid disease versus emergent impaired health 
status and symptoms. The finding of no association 
between corticosteroids prescribed for the acute illness 
and recovery might be confounded by a temporal change 
in practice patterns and in-hospital mortality during the 
study enrolment period. We did not account for multiple 
testing, which means that some statistically significant 
findings could be false positives; p values are provided in 
full for the reader to interpret (appendix pp 14–32). 
Validation in an independent cohort is required to 
confirm associations.
The outcome measures for this analysis had some 
limitations. For example, we did not have access to highly 
sensitive C-reactive protein, potentially underestimating 
the proportion of patients with elevated C-reactive 
protein. Although the MoCA is a validated, global 
measure of cognitive impairment, more in-depth testing 
is required to understand the precise deficits people are 
experiencing when describing “brain fog”. There may be 
other ongoing sequelae not captured by the outcome 
measures used. We used patient-perceived health status 
before hospital admission as a surrogate baseline for the 
symptom visual analogue scales, the EQ-5D-5L, and the 
WG-SS tool; these retrospective measures could be 
subject to recall bias.38 Our patient-centred definition for 
recovery in this report is a subjective definition based on 
patient perception and is likely to reflect who might seek 
post-COVID care. Although patient-perceived recovery 
might be affected by recall bias of pre-hospitalisation 
health, a similar five-point Likert scale has subsequently 
been developed and recommended as a core outcome 
measure for COVID-19 studies.39 In addition, patient-
perceived recovery corresponded well to the overall 
burden of disease identified in the recovery phenotypes, 
but how pre-existing comorbidities affect patient-
perceived recovery is unknown. Patient-perceived 
recovery will fail to identify pathological changes that 
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have not yet led to clinical expression, but which might 
become overt in later follow-up. Further comparisons are 
also required with recovery after other acute respiratory 
infections leading to hospitalisation and with those 
infected with COVID-19 but not hospitalised, to 
understand the specificity of our findings to COVID-19 
versus other critical illnesses and between those 
hospitalised versus those managed in the community.
Further analysis of the trajectory of recovery and 
linkage to primary and secondary health records within 
PHOSP-COVID will enable further discrimination. 
Notwithstanding these limitations, the magnitude of 
burden of physical and mental health is substantial post 
hospitalisation for COVID-19.
This is the first report from the PHOSP-COVID study, 
which includes biosampling for further immunological, 
multi-omic, and imaging endpoints, including multi-
modality MRI. These data will enable further analysis of 
systemic and organ-specific inflammation and damage. 
Further study of the trajectory of recovery, coupled with 
this greater mechanistic understanding, will inform a 
precision medicine approach to the clinical management 
of hospitalised COVID-19 survivors.
In conclusion, the majority of survivors of a hospital 
admission with COVID-19 are not fully recovered at 
5 months and have a substantial and diverse physical and 
mental health burden and negative effects on employment. 
We identified key factors associated with recovery and 
four distinct recovery phenotypes using cluster analysis 
according to mental, cognitive, and physical health. Our 
findings support the need for a proactive approach to 
clinical follow-up, with a holistic assessment to include 
symptoms of mental and physical health, and validated 
assessment of cognitive impairment. The four severity 
clusters highlight the potential to stratify care and the 
need for wide access to COVID-19 holistic clinical services, 
including mental health, memory and cognition, and 
rehabilitation services.
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